Lipocine Inc.
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Lipocine Inc. (Nasdaq: LPCN) is a clinical-stage specialty pharma company focused on oral drug delivery. Its commercial product is TLANDO, an oral testosterone replacement therapy approved by the FDA for adult males with hypogonadism, commercialized in the U.S. and Canada by licensing partner Verity Pharma. Pipeline programs include LPCN 1154 (oral brexanolone for postpartum depression), LPCN 1148 (oral formulation for liver cirrhosis) and LPCN 2101 (oral candidate for epilepsy). It is still listed and operating.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Verity Pharma rights
In January 2024 Verity Pharma received U.S. and Canadian commercial rights to TLANDO and took responsibility for regulatory and commercial work in both markets.
- Phase 3 miss and royalties
On April 2, 2026, topline Phase 3 results for oral brexanolone LPCN 1154 in postpartum depression did not meet the primary endpoint; the company reported $190,000 in TLANDO royalty revenue in Q2 2026.
- Health Canada approval
On October 7, 2026, Health Canada approved TLANDO for testosterone replacement therapy in adult males; Verity Pharma planned a Canadian launch by end of 2026. The company remained Nasdaq-listed and operating — no shutdown occurred.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.